Zobrazeno 1 - 10
of 449
pro vyhledávání: '"C. Hudis"'
Autor:
E. A. Perez, C. Hudis, J. Gralow, N. E. Davidson, A. E. McCullough, M. M. Reinholz, Amylou C. Dueck, B. Chen, David L. Rimm, K. Tenner, M. Vassilakopoulou, G. Fountzilas, H. Cheng, Karla V. Ballman, A. Psyrri
Publikováno v:
British Journal of Cancer
Background: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739ac0cd853337d3d1f649c325fad6ca
https://pubmed.ncbi.nlm.nih.gov/25117817
https://pubmed.ncbi.nlm.nih.gov/25117817
Autor:
C. Hudis
Publikováno v:
The Breast. 24:S3-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7186a7d54c84f318e32ab088fd3eb45
https://doi.org/10.1016/s0960-9776(15)70007-x
https://doi.org/10.1016/s0960-9776(15)70007-x
Autor:
M N, Fornier, A D, Seidman, M, Theodoulou, M E, Moynahan, V, Currie, M, Moasser, N, Sklarin, T, Gilewski, G, D'Andrea, R, Salvaggio, K S, Panageas, L, Norton, C, Hudis
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(12)
We conducted a randomized Phase II trial to directly compare toxicity, feasibility, and delivered dose intensities of two adjuvant dose-intensive regimens containing doxorubicin, paclitaxel, and cyclophosphamide for patients with node-positive breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::83857969c21025b72cd20e7b342e56bc
https://pubmed.ncbi.nlm.nih.gov/11751485
https://pubmed.ncbi.nlm.nih.gov/11751485
Autor:
B, McCormick, E, Strom, P S, Craighead, R, Kuske, C, Hudis, J, Ley, L, Margolis, B, Meyerwitz, E, Morris, J, Petrek, L, Pierce, T, Pisansky, R, Rabinovitch, N, Sneige, F, Vicini, D, Unger, K, Winter
Publikováno v:
International journal of radiation oncology, biology, physics. 51(3 Suppl 2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6c4d00cc085255b428165038aef12c02
https://pubmed.ncbi.nlm.nih.gov/11641016
https://pubmed.ncbi.nlm.nih.gov/11641016
Publikováno v:
Cancer chemotherapy and pharmacology.
Recent emphasis has focused on the development of an immunotherapeutic approach toward the treatment of breast cancer. In particular, evaluation of antibodies and vaccines are active areas of research. The monoclonal antibody trastuzumab (H), directe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1f2769ba8729cd16b462aaa7deeb0a8a
https://pubmed.ncbi.nlm.nih.gov/10950143
https://pubmed.ncbi.nlm.nih.gov/10950143
Autor:
C. Hudis
Publikováno v:
Progress in Anti-Cancer Chemotherapy ISBN: 9782287596926
In most parts of the West, breast cancer usually presents as a localized disease. [1] As a result, more and more patients are first treated surgically and then with radiation therapy, chemotherapy, and tamoxifen, as indicated, in the hopes of achievi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15ed2df3029444033b296682afab40c0
https://doi.org/10.1007/978-2-8178-0920-5_16
https://doi.org/10.1007/978-2-8178-0920-5_16
Autor:
G, D'Andrea, D, Fennelly, L, Norton, J, Baselga, T, Gilewski, C, Hudis, M E, Moynahan, G, Raptis, N, Sklarin, A, Surbone, M, Theodoulou, M A, Templeton, T J, Yao, A D, Seidman
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(2)
Motivated by the observation of preclinical synergy, a Phase I dose escalation study of edatrexate in combination with a 3-h paclitaxel infusion was performed in patients with advanced breast cancer to determine the maximum tolerated dose (MTD) of ed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd90bacbaeed03a7e33a9b35b34f3797
https://pubmed.ncbi.nlm.nih.gov/10037175
https://pubmed.ncbi.nlm.nih.gov/10037175
Autor:
C. Hudis
Publikováno v:
European Journal of Cancer Supplements. 4:45-46
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b0626171f0e39dfebcb54a20d3264ac
https://doi.org/10.1016/s1359-6349(06)80027-3
https://doi.org/10.1016/s1359-6349(06)80027-3
Autor:
C, Hudis
Publikováno v:
Oncology (Williston Park, N.Y.). 11(4 Suppl 3)
The recognition of paclitaxel's (Taxol) activity and non-cross-resistance with doxorubicin (Adriamycin) in the treatment of metastatic breast cancer has motivated study of the agent in the adjuvant setting. However, the ideal means of incorporating t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::45f3d2fc577608954c459f4bf4ae2e6c
https://pubmed.ncbi.nlm.nih.gov/9144685
https://pubmed.ncbi.nlm.nih.gov/9144685
Autor:
C, Hudis
Publikováno v:
Pharmacotherapy. 16(3 Pt 2)
Adjuvant chemotherapy improves the disease-free and overall survival of patients with resectable, early-stage breast cancer. However, the effect is modest, and we need means of increasing its impact. Retrospective and prospective studies on the effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::db3d245d71bf828613c2e2cee558e815
https://pubmed.ncbi.nlm.nih.gov/8726587
https://pubmed.ncbi.nlm.nih.gov/8726587